Delphi Genetics SA
" The aim of the project is to develop an antiviral gene therapy specifically targeting Covid-19. The benefits should be (i) targeting precisely the virus directly in lung cells allowing limitation of virus development from the starting point, (ii) restoring essential functions of the patient's cells and (iii) antibodies production by the patient due to reduction of viral load but not immediate clearance. In addition, the therapy could also be used preventively for people who come into regular contact with affected patients. The therapy is a gene therapy using AAV for patient administration. Delphi Genetics is developing and producing the plasmids required for targeting the virus and production of AAV. "
Contact: Cedric Szpirer Delphi Genetics SA 071 25 10 00

ULB - Fablab ULB
" A multidisciplinary team at the Fablab ULB (Université Libre de Bruxelles, Belgium) has developed and produced different open-source emergency protective solutions against Covid-19 for hospitals and caregivers. Most of these solutions have been developed within the global fablab network using digital fabrication machines (laser cutter, 3D printers,...) and open-source documentation which allowed other fablabs in the world to develop and produced these solutions locally. Face Protective Masks Face Protective Masks have been developed to protect caregivers from aerosol projection. Thanks to a lot of help (other fablabs, architectural offices, students, volunteers,...), we have produced more than 50 000 Protective Face Shields and distributed them in hospitals and to other caregivers. This project was made in collaboration with Fab-C (Charleroi), fablab Yourlab (Andenne) and the Hospital CHU Saint-Pierre in Brussels and supported by the Michel Crémer Foundation. Swabs...

Read more: Denis Terwagne, Professor - Victor Lévy, Professor - Alain Delchambre, Professor - Nicolas De Coster

Aesculape CRO Belgium BV
" Treatment of COVID 19 complications with antibodies "
Funding: partly public partly private
Contact : This email address is being protected from spambots. You need JavaScript enabled to view it. 0492 735931

ULB
" Inhaled ivermectin against COVID-19 study. Development of solution for nebulisation - preclinical safety and efficacy in animal models and clinical evaluation. CORONAVIRUS 2020 (CUR) research project submitted to FNRS on May 1, 2020. "
Funding: FNRS (requested)
Contact: Professor Karim Amighi Laboratory of Pharmaceutics and biopharmaceutics Université libre de Bruxelles (ULB) Faculty of Pharmacy Campus Plaine, CP-207 Boulevard du Triomphe, B-1050 Brussels - Belgium This email address is being protected from spambots. You need JavaScript enabled to view it.